Bacterial pneumonia
Conditions
Interventions
Experimental group:PPV23 revaccination
Sponsors
Sichuan Center for Disease Control and Prevention
Eligibility
Sex/Gender
All
Age
60 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 60 to 65 years old on the day of enrollment; 2. The subjects have signed the informed consent and signed the date; 3. The subjects are able to participate in all planned follow-up visits and were able to follow all trial procedures (e.g. complete diary card / contact card, return to visit); 4. The subjects in the study group had been vaccinated with 23 valent pneumococcal polysaccharide vaccine made in China for more than 5 years; 5. The control group had never been vaccinated with any pneumococcal vaccine; 6. Axillary temperature <= 37.0 degrees C.
Exclusion criteria
Exclusion criteria: 1. With a medical history with hypersensitiveness, eclampsia, epilepsy, cerebropathia and neurological illness; 2. Allergic to any ingredient of vaccine or with allergy history to any vaccine; 3. Subjects with immunodeficency or suspected impairment of immunologic function (e.g. caused by HIV), or subjects are in the process of immunosuppressor therapy(Taking orally injecting of steroid hormone); 4. Administration of immunoglobulins within 30 days prior to this study; 5. Acute febrile disease(temperature >= 37.degrees C) or infectious disease; 6. With a clearly diagnosed history of thrombocytopenia or other coagulopathy, may cause contraindications for subcutaneous injection; 7. With any serious chronic illness, acute infectious diseases, or respiratory diseases; 8. Suffering from serious cardiovascular diseases (pulmonary heart disease, pulmonary edema, hypertension can not be controlled to normal by drugs), liver and kidney diseases, diabetes with complications; 9. With any kind of infectious, purulent, or allergic skin diseases; 10. With any other factor that makes the investigator determines the subject is unsuitable for this study.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Antibody GMC level;Incidence of adverse reactions; | — |
Primary
| Measure | Time frame |
|---|---|
| Antibody double growth rate; | — |
Countries
China
Contacts
Public ContactQianli Ma
Sichuan Center for Disease Control and Prevention
Outcome results
None listed